Identifying biomarkers for diabetes remission after bariatric surgery
Identification of Human Circulating Adipocyte and Muscle Biomarkers Potentially Predictive of Diabetes Remission After Bariatric Surgery in Obese and Type 2 Diabetic Subjects.
This study is trying to find certain proteins in the body that can help predict if people with type 2 diabetes will see their diabetes improve after weight loss surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT05472883 on ClinicalTrials.gov |
What this trial studies
This study aims to identify human biomarkers that may predict diabetes remission in obese patients with type 2 diabetes following bariatric surgery. Researchers at the Institute of Metabolic and Cardiovascular Diseases will analyze blood, muscle, and adipose tissue samples from participants to measure the concentrations of nine candidate proteins associated with glucose control. The goal is to enhance existing clinical models for predicting diabetes remission by incorporating these biomarkers. Participants will be closely monitored for one year post-surgery to assess outcomes.
Who should consider this trial
Good fit: Ideal candidates are obese individuals with a body mass index of 35 kg/m² or higher who have type 2 diabetes and are scheduled for bariatric surgery.
Not a fit: Patients with type 1 diabetes, those who are pregnant or breastfeeding, and individuals unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of diabetes remission in patients undergoing bariatric surgery, potentially enhancing treatment outcomes.
How similar studies have performed: Other studies have explored biomarkers in diabetes remission, but this specific approach focusing on adipocyte and muscle biomarkers post-bariatric surgery is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obese patients of at least grade 2 (body mass index ≥ 35 kg/m²) * Type 2 diabetics * About to undergo bariatric surgery at the Toulouse University Hospital * Affiliated or beneficiaries of a social security plan. * Having provided a free, informed and written consent, signed Exclusion Criteria: * Type 1 diabetic subjects or Maturity-Onset Diabetes of the Youth. * Pregnant and breastfeeding women. * Vulnerable persons as defined in the Public Health Code: protected adults (guardianship, curators), unable to express their consent.
Where this trial is running
Toulouse
- Toulouse University Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Emilie MONTASTIER, MD — University Hospital, Toulouse
- Study coordinator: Emilie MONTASTIER, MD
- Email: montastier.e@chu-toulouse.fr
- Phone: 05 61 32 30 89
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.